Moxifloxacin therapy as a risk factor for clostridium difficile-associated disease during an outbreak: Attempts to control a new epidemic strain

被引：66

作者：

Biller, Priscilla ^{[1
]}

Shank, Beth ^{[1
]}

Lind, Leah ^{[1
]}

Brennan, Meghan ^{[1
]}

Tkatch, Lisa ^{[1
]}

Killgore, George ^{[1
]}

Thompson, Angela ^{[1
]}

McDonald, L. Clifford ^{[1
]}

机构：

[1] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA

来源：

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY | 2007年 / 28卷 / 02期

关键词：

D O I：

10.1086/511789

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

An outbreak of Clostridium difficile-associated disease ( CDAD) caused by the epidemic North American pulsed-field gel electrophoresis type 1 ( NAP1) strain began after a formulary change from levofloxacin to moxifloxacin. Cases of CDAD were associated with moxifloxacin use, but a formulary change back to levofloxacin failed to reduce rates of disease. Substituting use of one fluoroquinolone with use of another without also controlling the overall use of drugs from this class is unlikely to control outbreaks caused by the NAP1 strain of C. difficile.

引用

页码：198 / 201

页数：4

共 16 条

[1]

ALLEN SD, 2003, MANUAL CLIN MICROBIO, P845

[2]

Centers for Disease Control and Prevention, 2005, CLOSTR DIFF INF HEAL

[3] Hospitals battling outbreaks of C-difficile [J].